|
1
|
Zhao WL: Targeted therapy in T-cell
malignancies: Dysregulation of the cellular signaling pathways.
Leukemia. 24:13–21. 2010. View Article : Google Scholar : PubMed/NCBI
|
|
2
|
Kuro-o M, Matsumura Y, Aizawa H, Kawaguchi
H, Suga T, Utsugi T, Ohyama Y, Kurabayashi M, Kaname T, Kume E, et
al: Mutation of the mouse klotho gene leads to a syndrome
resembling ageing. Nature. 390:45–51. 1997. View Article : Google Scholar : PubMed/NCBI
|
|
3
|
Kurosu H, Yamamoto M, Clark JD, Pastor JV,
Nandi A, Gurnani P, McGuinness OP, Chikuda H, Yamaguchi M,
Kawaguchi H, et al: Suppression of aging in mice by the hormone
Klotho. Science. 309:1829–1833. 2005. View Article : Google Scholar : PubMed/NCBI
|
|
4
|
Kuro-o M: Klotho and aging. Biochim
Biophys Acta. 1790:1049–1058. 2009. View Article : Google Scholar : PubMed/NCBI
|
|
5
|
Yamamoto M, Clark JD, Pastor JV, Gurnani
P, Nandi A, Kurosu H, Miyoshi M, Ogawa Y, Castrillon DH, Rosenblatt
KP, et al: Regulation of oxidative stress by the anti-aging hormone
klotho. J Biol Chem. 280:38029–38034. 2005. View Article : Google Scholar : PubMed/NCBI
|
|
6
|
Zhou X and Wang X: Klotho: A novel
biomarker for cancer. J Cancer Res Clin Oncol. 141:961–969. 2015.
View Article : Google Scholar : PubMed/NCBI
|
|
7
|
Dai D, Wang Q, Li X, Liu J, Ma X and Xu W:
Klotho inhibits human follicular thyroid cancer cell growth and
promotes apoptosis through regulation of the expression of
stanniocalcin-1. Oncol Rep. 35:552–558. 2016.PubMed/NCBI
|
|
8
|
Rubinek T, Shulman M, Israeli S, Bose S,
Avraham A, Zundelevich A, Evron E, Gal-Yam EN, Kaufman B and Wolf
I: Epigenetic silencing of the tumor suppressor klotho in human
breast cancer. Breast Cancer Res Treat. 133:649–657. 2012.
View Article : Google Scholar : PubMed/NCBI
|
|
9
|
Chang B, Kim J, Jeong D, Jeong Y, Jeon S,
Jung SI, Yang Y, Kim KI, Lim JS, Kim C, et al: Klotho inhibits the
capacity of cell migration and invasion in cervical cancer. Oncol
Rep. 28:1022–1028. 2012.PubMed/NCBI
|
|
10
|
Yaktapour N, Ubelhart R, Schuler J, Aumann
K, Dierks C, Burger M, Pfeifer D, Jumaa H, Veelken H, Brummer T, et
al: Insulin-like growth factor-1 receptor (IGF1R) as a novel target
in chronic lymphocytic leukemia. Blood. 122:1621–1633. 2013.
View Article : Google Scholar : PubMed/NCBI
|
|
11
|
Vishwamitra D, Shi P, Wilson D, Manshouri
R, Vega F, Schlette EJ and Amin HM: Expression and effects of
inhibition of type I in sulin-like growth factor receptor tyrosine
kinase in mantle cell lymphoma. Haematologica. 96:871–880. 2011.
View Article : Google Scholar : PubMed/NCBI
|
|
12
|
Mathur R, Sehgal L, Braun FK, Berkova Z,
Romaguerra J, Wang M, Rodriguez MA, Fayad L, Neelapu SS and
Samaniego F: Targeting Wnt pathway in mantle cell
lymphoma-initiating cells. J Hematol Oncol. 8:632015. View Article : Google Scholar : PubMed/NCBI
|
|
13
|
Groen RW, Oud ME, Schilder-Tol EJ,
Overdijk MB, ten Berge D, Nusse R, Spaargaren M and Pals ST:
Illegitimate WNT pathway activation by beta-catenin mutation or
autocrine stimulation in T-cell malignancies. Cancer Res.
68:6969–6977. 2008. View Article : Google Scholar : PubMed/NCBI
|
|
14
|
Huang Z, Fang Z, Zhen H, Zhou L, Amin HM
and Shi P: Inhibition of type I insulin-like growth factor receptor
tyrosine kinase by picropodophyllin induces apoptosis and cell
cycle arrest in T lymphoblastic leukemia/lymphoma. Leuk Lymphoma.
55:1876–1883. 2014. View Article : Google Scholar : PubMed/NCBI
|
|
15
|
Jaffe ES: The 2008 WHO classification of
lymphomas: Implications for clinical practice and translational
research. Hematology (Am Soc Hematol Educ Program). 2009:523–531.
2009.
|
|
16
|
Abramovitz L, Rubinek T, Ligumsky H, Bose
S, Barshack I, Avivi C, Kaufman B and Wolf I: KL1 internal repeat
mediates klotho tumor suppressor activities and inhibits bFGF and
IGF-I signaling in pancreatic cancer. Clin Cancer Res.
17:4254–4266. 2011. View Article : Google Scholar : PubMed/NCBI
|
|
17
|
Chen B, Ma X, Liu S, Zhao W and Wu J:
Inhibition of lung cancer cells growth, motility and induction of
apoptosis by Klotho, a novel secreted Wnt antagonist, in a
dose-dependent manner. Cancer Biol Ther. 13:1221–1228. 2012.
View Article : Google Scholar : PubMed/NCBI
|
|
18
|
Li XX, Huang LY, Peng JJ, Liang L, Shi DB,
Zheng HT and Cai SJ: Klotho suppresses growth and invasion of colon
cancer cells through inhibition of IGF1R-mediated PI3K/AKT pathway.
Int J Oncol. 45:611–618. 2014.PubMed/NCBI
|
|
19
|
Aviel-Ronen S, Rubinek T, Zadok O, Vituri
A, Avivi C, Wolf I and Barshack I: Klotho expression in cervical
cancer: Differential expression in adenocarcinoma and squamous cell
carcinoma. J Clin Pathol. 69:53–57. 2016. View Article : Google Scholar : PubMed/NCBI
|
|
20
|
Lee J, Jeong DJ, Kim J, Lee S, Park JH,
Chang B, Jung SI, Yi L, Han Y, Yang Y, et al: The anti-aging gene
Klotho is a novel target for epigenetic silencing in human cervical
carcinoma. Mol Cancer. 9:1092010. View Article : Google Scholar : PubMed/NCBI
|
|
21
|
Chen T, Ren H, Thakur A, Yang T, Li Y,
Zhang S, Wang T and Chen M: Decreased level of klotho contributes
to drug resistance in lung cancer cells: Involving in
klotho-mediated cell autophagy. DNA Cell Biol. 35:751–757. 2016.
View Article : Google Scholar : PubMed/NCBI
|
|
22
|
Usuda J, Ichinose S, Ishizumi T, Ohtani K,
Inoue T, Saji H, Kakihana M, Kajiwara N, Uchida O, Nomura M, et al:
Klotho is a novel biomarker for good survival in resected large
cell neuroendocrine carcinoma of the lung. Lung Cancer. 72:355–359.
2011. View Article : Google Scholar : PubMed/NCBI
|
|
23
|
Xie B, Zhou J, Yuan L, Ren F, Liu DC, Li Q
and Shu G: Epigenetic silencing of Klotho expression correlates
with poor prognosis of human hepatocellular carcinoma. Hum Pathol.
44:795–801. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
24
|
Usuda J, Ichinose S, Ishizumi T, Ohtani K,
Inoue T, Saji H, Kakihana M, Kajiwara N, Uchida O, Nomura M, et al:
Klotho predicts good clinical outcome in patients with
limited-disease small cell lung cancer who received surgery. Lung
Cancer. 74:332–337. 2011. View Article : Google Scholar : PubMed/NCBI
|
|
25
|
Tilly H, da Gomes Silva M, Vitolo U, Jack
A, Meignan M, Lopez-Guillermo A, Walewski J, André M, Johnson PW,
Pfreundschuh M, et al: ESMO Guidelines Committee: Diffuse large
B-cell lymphoma (DLBCL): ESMO Clinical Practice Guidelines for
diagnosis, treatment and follow-up. Ann Oncol. 26:(Suppl 5).
v116–v125. 2015. View Article : Google Scholar : PubMed/NCBI
|
|
26
|
Wolf I, Levanon-Cohen S, Bose S, Ligumsky
H, Sredni B, Kanety H, Kuro-o M, Karlan B, Kaufman B, Koeffler HP,
et al: Klotho: A tumor suppressor and a modulator of the IGF-1 and
FGF pathways in human breast cancer. Oncogene. 27:7094–7105. 2008.
View Article : Google Scholar : PubMed/NCBI
|
|
27
|
Vishwamitra D, Curry CV, Alkan S, Song YH,
Gallick GE, Kaseb AO, Shi P and Amin HM: The transcription factors
Ik-1 and MZF1 downregulate IGF-IR expression in NPM-ALK(+) T-cell
lymphoma. Mol Cancer. 14:532015. View Article : Google Scholar : PubMed/NCBI
|
|
28
|
Ligumsky H, Rubinek T, Merenbakh-Lamin K,
Yeheskel A, Sertchook R, Shahmoon S, Aviel-Ronen S and Wolf I:
Tumor suppressor activity of klotho in breast cancer is revealed by
structure-function analysis. Mol Cancer Res. 13:1398–1407. 2015.
View Article : Google Scholar : PubMed/NCBI
|
|
29
|
Sun H, Gao Y, Lu K, Zhao G, Li X, Li Z and
Chang H: Overexpression of Klotho suppresses liver cancer
progression and induces cell apoptosis by negatively regulating
wnt/β-catenin signaling pathway. World J Surg Oncol. 13:3072015.
View Article : Google Scholar : PubMed/NCBI
|
|
30
|
Zhu Y, Xu L, Zhang J, Xu W, Liu Y, Yin H,
Lv T, An H, Liu L, He H, et al: Klotho suppresses tumor progression
via inhibiting PI3K/Akt/GSK3β/Snail signaling in renal cell
carcinoma. Cancer Sci. 104:663–671. 2013. View Article : Google Scholar : PubMed/NCBI
|
